Dr. Daniel Chelsky is an experienced science and business executive with a focus on proteomics, diagnostics and product development. He devotes half his time as CSO of Caprion Biosciences, a proteomics research services company with a focus on biomarkers, diagnostics and microbiome research. He is also currently working to launch two diagnostics start-ups in cancer and Alzheimer’s disease, respectively. Previously he served as President of BioSignal, a subsidiary of PerkinElmer focused on GPCR-related research and reagents. He has also held positions as Sr. Director of Biology at Pharmacopeia, a combinatorial chemistry company, Director of Drug Discovery at Onyx Pharmaceuticals, and Principal Investigator at DuPont Merck Pharmaceuticals. He received his Ph.D. at the University of Oregon and was an American Cancer Society fellow at UC Berkeley.